SCHEMBL7083124

SCHEMBL7083124

Cc1cnc(Cc2cc(Br)cc(Cc3ccccc3)c2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 1/20 0.40
CYP2D6 P10635 4/20 0.36
HRH1 P35367 1/20 0.36
ALDH1A1 P00352 4/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CALM1 P0DP23 1/20 0.35
CYP1A2 P05177 5/20 0.34
CLK4 Q9HAZ1 5/20 0.34
CYP3A4 P08684 4/20 0.34
LTA4H P09960 1/20 0.34
TSHR P16473 2/20 0.33
AOC3 Q16853 1/20 0.33
HSD17B10 Q99714 3/20 0.33
LNPEP Q9UIQ6 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13562464 0.86 HTR2B (0.46) HTR2BCYP2D6HRH1ALDH1A1RAB9A
SCHEMBL7082280 0.81 LMNA (0.49) HTR2BALDH1A1LNPEPKMT2A
SCHEMBL7079566 0.78 MEN1 (0.40) HTR2BCYP2D6ALDH1A1L3MBTL1CALM1
SCHEMBL22957984 0.77 LTA4H (0.40) HTR2BCYP2D6HRH1CALM1CYP3A4
SCHEMBL7077360 0.75 ALDH1A1 (0.42) ALDH1A1RAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL27072915 0.75 CALM1 (0.55) HTR2BALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL6481288 0.73 CALM1 (0.60) ALDH1A1TDP1CALM1LTA4HTSHR
SCHEMBL12150537 0.72 TP53 (0.50) ALDH1A1CALM1CYP1A2LTA4HTSHR
SCHEMBL19034706 0.70 CYP1A2 (0.46) CYP2D6TDP1L3MBTL1CYP1A2CLK4
SCHEMBL18763010 0.70 TP53 (0.46) HTR2BALDH1A1RAB9ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 HTR2B 3848/4885CYP2D6 501/4885HRH1 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.